CD80、CD83、CD86检测在非小细胞肺癌中的应用价值
|
摘要
目的探讨CD80、CD83、CD86检测在非小细胞肺癌(NSCLC)中的临床意义。方法收集2012年1月—2015年12月在台州市第一人民医院治疗的NSCLC患者113例及健康对照组30例。采用流式细胞术分析NSCLC患者和健康对照者外周血CD80、CD83、CD86的表达水平。数据比较采用t检验和方差分析,患者生存时间采用Kaplan-Meier法和log-rank分析来确定是否有差异。结果 NSCLC患者CD80、CD83、CD86水平明显低于正常对照组(t=10.026、4.963、4.870,均P<0.05),不同分期患者CD80、CD83水平差异有统计学意义(F=12.750、9.481,均P<0.05)。NSCLC患者术后CD80、CD83、CD86水平较术前明显升高(t=-3.648、-4.621、-4.257,均P<0.05)。CD80水平较高的NSCLC患者具有更好的生存率(P=0.040),而CD83、CD86水平与生存率无关(P=0.118、0.084)。结论检测NSCLC患者CD80、CD83、CD86水平具有一定价值,CD80、CD83与肿瘤分期密切相关,且CD80是NSCLC患者生存时间的独立预测因子。
Objective To investigate the clinical significance of CD80,CD83 and CD86 of non-small cell lung cancer(NSCLC) patients. Methods One hundred and thirteen cases of patients with NSCLC and 30 cases of healthy controls from January,2012 to December,2015 in the first people's hospital of Taizhou were collected. The expression of CD80,CD83 and CD86 in the peripheral blood of patients with NSCLC and healthy controls were analyzed by flow cytometry.Comparisons were made using the t test and variance test. Kaplan-Meier plots and log rank analysis were applied to determine the significance of differences in patient's survival time. Results The levels of CD80,CD83,CD86 in NSCLC patients were significantly lower than those of normal controls( t = 10. 026,4. 963,4. 870,all P < 0. 05),and CD80,CD83 were significantly difference in different TNM stage( F = 12. 750,9. 481,all P < 0. 05). The levels of CD80,CD83 and CD86 in NSCLC patients after operation were significantly improved than that before operation( t =-3. 648,-4. 621,-4. 257,all P < 0. 05). The NSCLC patients with high level of CD80 had better survival rate( P = 0. 040),while CD83 and CD86 had not( P = 0. 118,0. 084). Conclusion The detection of CD80,CD83 and CD86 may be valuable in NSCLC patients. CD80,CD83 are closely associated with TNM stage,and CD80 is an independent predictor of survival time.
Objective To investigate the clinical significance of CD80,CD83 and CD86 of non-small cell lung cancer(NSCLC) patients. Methods One hundred and thirteen cases of patients with NSCLC and 30 cases of healthy controls from January,2012 to December,2015 in the first people's hospital of Taizhou were collected. The expression of CD80,CD83 and CD86 in the peripheral blood of patients with NSCLC and healthy controls were analyzed by flow cytometry.Comparisons were made using the t test and variance test. Kaplan-Meier plots and log rank analysis were applied to determine the significance of differences in patient's survival time. Results The levels of CD80,CD83,CD86 in NSCLC patients were significantly lower than those of normal controls( t = 10. 026,4. 963,4. 870,all P < 0. 05),and CD80,CD83 were significantly difference in different TNM stage( F = 12. 750,9. 481,all P < 0. 05). The levels of CD80,CD83 and CD86 in NSCLC patients after operation were significantly improved than that before operation( t =-3. 648,-4. 621,-4. 257,all P < 0. 05). The NSCLC patients with high level of CD80 had better survival rate( P = 0. 040),while CD83 and CD86 had not( P = 0. 118,0. 084). Conclusion The detection of CD80,CD83 and CD86 may be valuable in NSCLC patients. CD80,CD83 are closely associated with TNM stage,and CD80 is an independent predictor of survival time.
引文
[1]Chen Z,Fillmore CM,Hammerman PS,et al.Non-small-cell lung cancers:a heterogeneous set of diseases[J].Nat Rev Cancer,2014,14(8):535-546.
[2]王丽萍.肺癌免疫治疗现状及展望[J].中华实用诊断与治疗杂志,2017,31(2):105-110.
[3]Zhao M,Li H,Li L,et al.Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients[J].Exp Ther Med,2014,7(5):1403-1407.
[4]Liu Y,Tian X,Jiang S,et al.Umbilical cord blood-derived dendritic cells infected by adenovirus for SP17 expression induce antigen-specific cytotoxic T cells against NSCLC cells[J].Cell Immunol,2015,298(1):18-24.
[5]Zhang L,Yang X,Sun Z,et al.Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer[J].Oncol Lett,2016,11(4):2605-2610.
[6]Takahashi H,Shimodaira S,Ogasawara M,et al.Lung adenocarcinoma may be a more susceptive subtype to adendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers:a multicenter retrospective analysis[J].Cancer Immunol Immunother,2016,65(9):1099-1111.
[7]Schaedler E,Remy-Ziller C,Hortelano J,et al.Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod(Li28)improves local immune defense against tumors[J].Vaccine,2017,35(4):577-585.
[8]孙福丹,庞剑.DC/CIK治疗非小细胞肺癌的临床研究现状[J].继续医学教育,2016,30(5):93-94.
[9]徐瑞剑,王志强,毕克毅,等.肺癌细胞裂解物刺激树突状细胞诱导产生免疫应答的实验研究[J].中国冶金工业医学杂志,2014,31(4):373-375.
[10]霍忠超,刘晓霞,王雪玲,等.负载肺癌全抗原的自体树突状细胞诱导T细胞反应的体外研究[J].疑难病杂志,2015,14(2):175-178.
[11]杭晓声,史央,李丽,等.树突状细胞免疫治疗晚期非小细胞肺癌的临床观察[J].肿瘤防治研究,2012,39(2):205-209.
[12]张锦鑫,李霄,郭恒,等.负载肿瘤细胞抗原的树突状细胞联合奥沙利铂抑制胰腺癌细胞Bx PC-3增殖的实验研究[J].现代生物医学进展,2013,13(23):4455-4458.
[13]Liu X,Li J,Liu Y,et al.Calreticulin acts as an adjuvant to promote dendritic cell maturation and enhances antigen-specific cytotoxic T lymphocyte responses against non-small cell lung cancer cells[J].Cell Immumol,2016,300(4):46-53.
[14]Huang A,Zhang B,Wang B,et al.Increased CD14(+)HLA-DR(-/low)myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients[J].Cancer Immunol Immunother,2013,62(9):1439-1451.
[15]Urbanova L,Hradilova N,Moserova I,et al.High hydrostatic pressure affects antigenic pool in tumor cells:Implication for dendritic cellbased cancer immunotherapy[J].Immunol Lett,2017,187(2):27-34.
[16]Teramoto K,Ozaki Y,Hanaoka J,et al.Predictive biomarkers and effectiveness of MUC1-targeted dendritic-cell-based vaccine in patients with refractory non-small cell lung cancer[J].Ther Adv Med Oncol,2017,9(3):147-157.
[17]Hradilova N,Sadilkova L,Palata O,et al.Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy[J].PLo S One,2017,12(2):171-179.
[18]Zhou C,Liu D,Li J,et al.Chemotherapy plus dendritic cells co-cultured with cytokine-induced killer cells versus chemotherapy alone to treat advanced non-small-cell lung cancer:A meta-analysis[J].Oncotarget,2016,7(52):86500-86510.
[19]林兴,黄云超,吴榕龙,等.树突状细胞亚群在非小细胞肺癌及癌旁组织中分布特点及临床意义[J].福建医科大学学报,2013,47(5):274-278.
[20]Ma J,Liu H,Wang X.Effect of ginseng polysaccharides and dendritic cells on the balance of Th1/Th2 T helper cells in patients with nonsmall cell lung cancer[J].J Tradit Chin Med,2014,34(6):641-645.
[2]王丽萍.肺癌免疫治疗现状及展望[J].中华实用诊断与治疗杂志,2017,31(2):105-110.
[3]Zhao M,Li H,Li L,et al.Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients[J].Exp Ther Med,2014,7(5):1403-1407.
[4]Liu Y,Tian X,Jiang S,et al.Umbilical cord blood-derived dendritic cells infected by adenovirus for SP17 expression induce antigen-specific cytotoxic T cells against NSCLC cells[J].Cell Immunol,2015,298(1):18-24.
[5]Zhang L,Yang X,Sun Z,et al.Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer[J].Oncol Lett,2016,11(4):2605-2610.
[6]Takahashi H,Shimodaira S,Ogasawara M,et al.Lung adenocarcinoma may be a more susceptive subtype to adendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers:a multicenter retrospective analysis[J].Cancer Immunol Immunother,2016,65(9):1099-1111.
[7]Schaedler E,Remy-Ziller C,Hortelano J,et al.Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod(Li28)improves local immune defense against tumors[J].Vaccine,2017,35(4):577-585.
[8]孙福丹,庞剑.DC/CIK治疗非小细胞肺癌的临床研究现状[J].继续医学教育,2016,30(5):93-94.
[9]徐瑞剑,王志强,毕克毅,等.肺癌细胞裂解物刺激树突状细胞诱导产生免疫应答的实验研究[J].中国冶金工业医学杂志,2014,31(4):373-375.
[10]霍忠超,刘晓霞,王雪玲,等.负载肺癌全抗原的自体树突状细胞诱导T细胞反应的体外研究[J].疑难病杂志,2015,14(2):175-178.
[11]杭晓声,史央,李丽,等.树突状细胞免疫治疗晚期非小细胞肺癌的临床观察[J].肿瘤防治研究,2012,39(2):205-209.
[12]张锦鑫,李霄,郭恒,等.负载肿瘤细胞抗原的树突状细胞联合奥沙利铂抑制胰腺癌细胞Bx PC-3增殖的实验研究[J].现代生物医学进展,2013,13(23):4455-4458.
[13]Liu X,Li J,Liu Y,et al.Calreticulin acts as an adjuvant to promote dendritic cell maturation and enhances antigen-specific cytotoxic T lymphocyte responses against non-small cell lung cancer cells[J].Cell Immumol,2016,300(4):46-53.
[14]Huang A,Zhang B,Wang B,et al.Increased CD14(+)HLA-DR(-/low)myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients[J].Cancer Immunol Immunother,2013,62(9):1439-1451.
[15]Urbanova L,Hradilova N,Moserova I,et al.High hydrostatic pressure affects antigenic pool in tumor cells:Implication for dendritic cellbased cancer immunotherapy[J].Immunol Lett,2017,187(2):27-34.
[16]Teramoto K,Ozaki Y,Hanaoka J,et al.Predictive biomarkers and effectiveness of MUC1-targeted dendritic-cell-based vaccine in patients with refractory non-small cell lung cancer[J].Ther Adv Med Oncol,2017,9(3):147-157.
[17]Hradilova N,Sadilkova L,Palata O,et al.Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy[J].PLo S One,2017,12(2):171-179.
[18]Zhou C,Liu D,Li J,et al.Chemotherapy plus dendritic cells co-cultured with cytokine-induced killer cells versus chemotherapy alone to treat advanced non-small-cell lung cancer:A meta-analysis[J].Oncotarget,2016,7(52):86500-86510.
[19]林兴,黄云超,吴榕龙,等.树突状细胞亚群在非小细胞肺癌及癌旁组织中分布特点及临床意义[J].福建医科大学学报,2013,47(5):274-278.
[20]Ma J,Liu H,Wang X.Effect of ginseng polysaccharides and dendritic cells on the balance of Th1/Th2 T helper cells in patients with nonsmall cell lung cancer[J].J Tradit Chin Med,2014,34(6):641-645.